AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9506565
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate with leucovorin rescue (I.V. MTX)
Trial: 7827349
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic patients with microalbuminuria
Trial: 26578409
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day arginyl-fructose
Trial: 3302875
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CFX) 1 g/24 h im
Trial: 3302875
Drug: Amikacin (AMK)
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin (AMK) 500 mg/24 h im
Trial: 31992377
Drug: Betaine (BT)
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine (BT) 0.6 g/kg DM without RPFA
Trial: 31992377
Drug: Betaine (BT)
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine (BT) 0.6 g/kg DM with RPFA
Trial: 27138546
Drug: Rifampicin 10
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 mg
Trial: 27138546
Drug: Rifampicin 20
RxNorm normalized name: Rifampicin 20 mg/mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 20 mg
Trial: 27138546
Drug: Rifampicin 100
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 100 mg
Trial: 19297116
Drug: Computer agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer agent explanation of consent form
Trial: 17194911
Drug: XELOX (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (intravenous oxaliplatin plus oral capecitabine; 3‐week cycle for eight cycles)
Trial: 31240541
Drug: APAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP therapy
Trial: 31779693
Drug: Supervised progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised progressive strength training and oral protein supplement during hospitalization and at home 3 days/week for 4 weeks after discharge
Trial: 31779693
Drug: Supervised progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised progressive strength training and oral protein supplement
Trial: 25827594
Drug: Bolus whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus whey protein (WP; 20 g)
Trial: 25827594
Drug: Low-dose leucine-enriched
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leucine-enriched essential amino acids (LEAA; 3 g, 40% leucine)
Trial: 21518557
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (rapid steroid reduction to 10 mg/d)
Trial: 21518557
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard corticosteroid therapy)
Trial: 10514159
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg/day)
Trial: 7557557
Drug: Picotamide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (450 mg/day)
Trial: 8420815
Drug: Picotamide (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (900 mg/day)
Trial: 7557557
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Picotamide (150 mg/day and 450 mg/day respectively)
Trial: 30918121
Drug: Deferred PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred PrEP (DEF) with self-reported diagnosis of syphilis, rectal chlamydia (CT) or rectal gonorrhoea (GC) in the previous 12 months
Trial: 30918121
Drug: Deferred PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred PrEP (DEF) lacking both syphilis/rectal CT/GC and multiple ncRAI partners
Trial: 19473224
Drug: Individual art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual art therapy sessions for 1 h/week (n = 20)
Trial: 11829723
Drug: Deoxycholate or
RxNorm normalized name: ursodeoxycholate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxycholate or liposomal formulations of amphotericin B
Trial: 2676609
Drug: Coumarin (1,2‐benzopyrone)
RxNorm normalized name: 3,3'-methylenebis(4-hydroxy-1,2-benzopyrone)
DrugBank: Coumarin (DB04665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin (1,2‐benzopyrone) daily oral dose of 50 mg
Trial: 16792
Drug: Methyprylon 300
RxNorm normalized name: methyprylon 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyprylon 300 mg
Trial: 29999197
Drug: Abametapir lotion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abametapir lotion, 0.74%
Trial: 26033416
Drug: Parenteral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral oestrogen
Trial: 24531755
Drug: Vitamin C-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C-rich apple juice (VCR) - 60 mg/L vitamin C and 510 mg catechin equivalent/L
Trial: 24531755
Drug: Polyphenol-rich apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich apple juice (PR) - 22 mg/L vitamin C and 993 mg catechin equivalent/L
Trial: 23094031
Drug: Caffeine (2*200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2*200 mg)
Trial: 20368553
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg every 2 weeks) plus interferon alfa-2a (9 MIU subcutaneously three times a week)
Trial: 20368553
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus IFN (postprotocol therapy including a tyrosine kinase inhibitor)
Trial: 20368553
Drug: IFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN plus placebo (postprotocol therapy including a tyrosine kinase inhibitor)
Trial: 10372726
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midfollicular phase (MFP)
Trial: 10372726
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during late follicular phase (LFP)
Trial: 10372726
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midluteal phase (MLP)
Trial: 2115446
Drug: Rectal solution
RxNorm normalized name: Rectal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal solution (100 mg flecainide)
Trial: 2115446
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (100 mg flecainide)
Trial: 2115446
Drug: Tablet (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (100 mg flecainide)
Trial: 7002205
Drug: Ritodrine (long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (long infusion)
Trial: 7002205
Drug: Ritodrine (short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (short infusion)
Trial: 7002205
Drug: Ritodrine (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (intramuscular injection)
Trial: 7002205
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (bed rest and sedatives)
Trial: 2687586
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine
Trial: 17729016
Drug: Modafinil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100-400 mg/day or 200 mg/day)
Trial: 12167574
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and 5-Fluorouracil chemotherapy (pulse regimen)
Trial: 12167574
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and 5-Fluorouracil chemotherapy (continuous infusion regimen)
Trial: 7712759
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of famotidine (1.7 mg/hr for 24 hrs)
Trial: 7712759
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of famotidine (20 mg i.v. over 10 mins, every 12 hrs)
Trial: 1506045
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 16.5% immune serum globulin (ISG)
Trial: 29851803
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser acupuncture (LA without laser output) plus conventional treatment
Trial: 20606402
Drug: High-dose adecatumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adecatumumab (6 mg/kg)
Trial: 20606402
Drug: Low-dose adecatumumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adecatumumab (2 mg/kg)
Trial: 17500020
Drug: Oral co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-trimoxazole for 3 months
Trial: 15012690
Drug: Aspirin 200
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 200 mg daily for 8 weeks
Trial: 15012690
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for 8 weeks
Trial: 11058789
Drug: Polymorphisms in
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation)
Trial: 11058789
Drug: Polymorphisms in
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation) combined with APOE varepsilon4 genotype
Trial: 9304162
Drug: No thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thrombolytic treatment
Trial: 27874837
Drug: No-SP group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-SP group (nonspiritual therapy)
Trial: 24553973
Drug: Inhaled Budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Budesonide
Trial: 12194619
Drug: Holding a
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holding a weighted spoon (248 g)
Trial: 12194619
Drug: Holding a
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holding a built-up spoon (108 g)
Trial: 12194619
Drug: Holding a
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holding a built-up spoon while wearing a weighted wrist cuff (470 g)
Trial: 7880662
Drug: Eltanolone 4
RxNorm normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 300 ml h‐1
Trial: 7880662
Drug: Eltanolone 4
RxNorm normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 600 ml h‐1
Trial: 7880662
Drug: Eltanolone 4
RxNorm normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 1200 ml h‐1
Trial: 31222771
Drug: Hyperinsulinaemia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinaemia and insulin resistance (IR)
Trial: 25130167
Drug: Kegel exercises
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kegel exercises with vaginal spheres, performed twice daily, 5 days/week for 6 months.
Trial: 25130167
Drug: Kegel exercises
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kegel exercises without vaginal spheres (control group), performed twice daily, 5 days/week for 6 months.
Trial: 22122814
Drug: Ibuprofen sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen sodium dihydrate 400 mg
Trial: 12162473
Drug: Conventional ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional ibuprofen 400 mg
Trial: 19168461
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP) as a diuretic
Trial: 16765532
Drug: Intravenous L-alanyl-L-glutamine
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day
Trial: 11736859
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (100 mg capsules) for 14 days
Trial: 11736859
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide (50 mg) on day 1 or day 7
Trial: 7848388
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Trial: 7848388
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Trial: 7848388
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of saline added to 0.5% bupivacaine
Trial: 22812691
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 600 mg on days 1-3 and 1,200 mg on days 4-9, once daily
Trial: 22812691
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) 300 mg on days 1-3 and 600 mg on days 4-9, twice daily
Trial: 19419555
Drug: Amlexanox oral
RxNorm normalized name: amlexanox Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlexanox oral adhesive pellicles
Trial: 19419555
Drug: Amlexanox oral
RxNorm normalized name: amlexanox Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlexanox oral adhesive tablets
Trial: 17466972
Drug: 1-desamino-8-D-arginine-vasopressin administration
RxNorm normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-desamino-8-D-arginine-vasopressin administration after water loading
Trial: 11231774
Drug: Frequent aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent aspirin use (>/=180 days per year)
Trial: 9576406
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg/day)
Trial: 7935702
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg orally twice daily)
Trial: 3428345
Drug: Carvedilol 50
RxNorm normalized name: carvedilol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 50 mg capsule
Trial: 3428345
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg i.v.
Trial: 3428345
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg capsule
Trial: 3428345
Drug: Carvedilol 50
RxNorm normalized name: carvedilol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 50 mg suspension
Trial: 23149081
Drug: Expectancy assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy assessment before first infusion
Trial: 21681585
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BGC20-1531
Trial: 21681585
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BGC20-1531
Trial: 18365505
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections into internal anal sphincter
Trial: 17052565
Drug: Acetaminophen extended
RxNorm normalized name: Acetaminophen Extended-Release
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen extended release 1,300 mg 3 times daily
Trial: 17052565
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg 3 times daily
Trial: 12747651
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml (12.5 mg) triamcinolone acetonide intravitreally
Trial: 12747651
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml balanced salt solution after retrobulbar anesthesia
Trial: 11149273
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide)
Trial: 2867598
Drug: RP 40
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP 40 749 (150 mg)
Trial: 22476239
Drug: Lateral classic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral classic TAP block with 30 mL ropivacaine 0.375%
Trial: 22476239
Drug: Dual 15
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dual 15 mL injections at the upper intercostal and lateral classic TAP plexuses
Trial: 20573492
Drug: Antiwei (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiwei (6 g, twice daily for three days)
Trial: 25824314
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment approaches
Trial: 31109232
Drug: Traditional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatments (Control)
Trial: 21651447
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium 1 mg/day
Trial: 21651447
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium 2 mg/day
Trial: 2156277
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg L-tryptophan administered intravenously over 20 min
Trial: 2156277
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg L-tryptophan
Trial: 21762225
Drug: TPI ASM8
RxNorm normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPI ASM8 (4 mg b.i.d.)
Trial: 21762225
Drug: TPI ASM8
RxNorm normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPI ASM8 (8 mg o.d.)
Trial: 17348884
Drug: Transmucosal implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmucosal implant placement (test group)
Trial: 14732421
Drug: Social reinforcement
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social reinforcement of aftercare group therapy attendance
Trial: 10066843
Drug: rtPA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rtPA treatment
Trial: 8148045
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both interventions)
Trial: 3075625
Drug: Contralateral eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral eyes (no treatment)
Trial: 21079818
Drug: Atorvastatin (ATO)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (ATO) 40 mg/day